Marshall Wace, LLP
- SEC CIK
- 0001318757
- Latest filing
- Aug 13, 2026
CLDX holding history
Celldex Therapeutics, Inc. in every 13F filed by Marshall Wace, LLP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
CLDX overviewAll 13F holders of CLDXFull Q2 2026 holdings
- Shares (Q4 2024)
- 0
- Sold out in Q4 2024
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 11
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q4 2024 | 0 | $0 | 0.0% | −276,728−100.0% | Sold out | Holders |
| Q3 2024 | 276,728 | $9.41M | <0.1% | −1,101,140−79.9% | Reduced | Holders |
| Q2 2024 | 1,377,868 | $51.0M | 0.1% | +479,068+53.3% | Added | Holders |
| Q1 2024 | 898,800 | $37.7M | 0.1% | −381,284−29.8% | Reduced | Holders |
| Q4 2023 | 1,280,084 | $50.8M | 0.1% | +741,765+137.8% | Added | Holders |
| Q3 2023 | 538,319 | $14.8M | <0.1% | +248,796+85.9% | Added | Holders |
| Q2 2023 | 289,523 | $9.82M | <0.1% | −44,143−13.2% | Reduced | Holders |
| Q1 2023 | 333,666 | $12.0M | <0.1% | −333,083−50.0% | Reduced | Holders |
| Q4 2022 | 666,749 | $29.7M | 0.1% | +14,028+2.1% | Added | Holders |
| Q3 2022 | 652,721 | $18.3M | <0.1% | +632,698+3,159.9% | Added | Holders |
| Q2 2022 | 20,023 | $539.0K | <0.1% | +20,023 | New | Holders |
| Q2 2021 | 0 | $0 | 0.0% | −20,580−100.0% | Sold out | Holders |
| Q1 2021 | 20,580 | $423.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.